Discovery of Novel Selective Norepinephrine Inhibitors: 1-(2-Morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-Dioxides (WYE-114152)
作者:David J. O’Neill、Adedayo Adedoyin、Jenifer A. Bray、Darlene C. Deecher、Andrew Fensome、Joel A. Goldberg、Jim Harrison、Liza Leventhal、Charles Mann、Lilly Mark、Lisa Nogle、Nicole R. Sullivan、Taylor B. Spangler、Eugene A. Terefenko、Eugene J. Trybulski、Albert J. Uveges、An Vu、Garth T. Whiteside、Puwen Zhang
DOI:10.1021/jm200733r
日期:2011.10.13
4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols led to the identification of a new series of 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides that are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound 10b (WYE-114152) had low nanomolar hNET
先前鉴定的4- [3-芳基-2,2-二氧化物-2,1,3-苯并噻二唑-1(3 H)-基] -1-(甲基氨基)丁烷-2-醇的顺序修饰导致鉴定系列新的1-(2-吗啉-2-基乙基)-3-芳基-1,3-二氢-2,1,3-苯并噻二唑2,2-二氧化物是去甲肾上腺素转运蛋白的有效和选择性抑制剂血清素和多巴胺转运蛋白。一种代表性的化合物10b(WYE-114152)具有较低的纳摩尔hNET效价(IC 50 = 15 nM),并且在hSERT(> 430倍)和hDAT(> 548倍)上对hNET具有良好的选择性。口服给药后10b还可生物利用,并在急性,炎性和神经性疼痛的大鼠模型中证明了疗效。